3 results about "Mrna transfection" patented technology

This invention belongs to the field of biomedical technology, specifically relating to a delivery system for type III collagen mRNA and its applications. The nucleic acid delivery system of this invention includes a delivery carrier and a delivered nucleic acid, wherein the nucleic acid is collagen mRNA, and the delivery carrier includes one or more of modified amino acids, growth factors, and polymeric materials. Through intradermal injection, the delivery system of this invention can be administered to the dermal layer of the skin and enter relevant cells, utilizing endogenous cellular proteins to achieve mRNA transfection, forming natural human type III collagen. This invention avoids the immunogenicity risks and structural inactivation problems associated with exogenous collagen injections, and can efficiently and safely replenish non-regenerative type III collagen in tissues. It can be used for various indications such as treating skin aging, promoting wound healing, reducing scar formation, and improving vascular elasticity.

Leveraging the extensive surface area of the lungs for gene therapy, inhalation route offers distinct advantages for delivery. Clinical nebulizers that employ vibrating mesh technology are the standard choice for converting liquid medicines into aerosols. However, they have limitations when it comes to delivering mRNA through inhalation, including severe damage to nanoparticles due to shearing forces. A microfluidic aerosolization platform (MAP) can preserves the structural and physicochemical integrity of lipid nanoparticles, enabling safe and efficient mRNA delivery to the respiratory system. Results demonstrated the superiority of the novel microfluidic aerosolizer over the conventional vibrating mesh nebulizer, as it avoided problems such as particle aggregation, loss of mRNA encapsulation, and deformation of nanoparticle morphology. Notably, aerosolized nanoparticles generated by the microfluidic aerosolization platform led to enhanced transfection efficiency across various cell lines. In vivo experiments with mice that inhaled these aerosolized nanoparticles revealed successful, lung-specific mRNA transfection without observable signs of toxicity. This pioneering MAP represents a significant advancement for the pulmonary gene therapy, enabling precise and effective delivery of aerosolized nanoparticles.